CP 101 - Finch Therapeutics

Drug Profile

CP 101 - Finch Therapeutics

Alternative Names: CP-101 - Finch

Latest Information Update: 06 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Crestovo
  • Developer Finch Therapeutics Group
  • Class Bacteria; Probiotics
  • Mechanism of Action Metagenome modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Clostridium-difficile-infections

Most Recent Events

  • 01 Mar 2018 CP 101 - Finch Therapeutics receives Fast Track designation for Clostridium difficile infections [PO,Capsule] (Recurrent) in USA
  • 23 Oct 2017 Crestovo has merged with Finch Therapeutics to form Finch Therapeutics Group
  • 23 Oct 2017 Finch has patents pending for CP 101
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top